Lupin shares rose 2.21% to ₹2,393.80 following the announcement of US FDA approval, marking a significant turnaround from the previous day's decline. As reported by Business Standard, this positive market reaction reflects investor confidence in the regulatory milestone and the company's strategic positioning in the prostate cancer treatment market. The stock's recovery demonstrates how quickly market sentiment can shift when regulatory hurdles are cleared, with the approval providing immediate sentiment support for the company's growth prospects.
Drugmaker Lupin Ltd announced on Friday that it has received tentative approval from the US Food and Drug Administration (US FDA) for its generic version of Enzalutamide Tablets used in the treatment of prostate cancer. According to the company's regulatory filing, the approval covers Lupin's Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in strengths of 40 mg, 80 mg, 120 mg and 160 mg. As reported by CNBC TV18, the approval was announced on June 26, 2026, marking a significant regulatory milestone for the company. The approval covers the 40 mg and 80 mg tablets as bioequivalent to Astellas' reference listed drug (RLD), Xtandi, for the approved indication. This approval represents a strategic addition to the company's oncology portfolio and positions it for entry into the prostate cancer treatment market once regulatory barriers are removed. The tentative approval means Lupin's generic drug meets all safety and efficacy standards, but it cannot be sold yet due to existing patents or marketing exclusivities held by the original drug maker.
The tentative approval positions Lupin to compete in a $3.5 billion annual US market for Enzalutamide, making it one of the largest market opportunities in the prostate cancer segment for generic manufacturers. The reference drug, Xtandi, has annual US sales of approximately $3.5 billion, representing a high-value generic opportunity due to the high volume of prescriptions in North America. While the revenue impact is delayed until existing patent or regulatory exclusivity expires, the approval increases the Net Present Value (NPV) of Lupin's pipeline and reduces long-term revenue uncertainty. The company noted that while Xtandi is currently marketed in 40 mg and 80 mg strengths, its proposed 120 mg and 160 mg tablets are expected to provide healthcare professionals and patients with additional dosing flexibility, offering alternative dosing options for healthcare providers and patients. The approval provides immediate sentiment support for the company, with analysts likely to re-rate forward P/E multiples as the regulatory validation strengthens long-term fundamentals.
According to the company, globally, prostate cancer is among the most commonly diagnosed cancers in men. Enzalutamide is used to treat advanced forms of the disease and works by blocking the effects of male hormones that help cancer cells grow. The drug represents a significant treatment option for patients with advanced prostate cancer, addressing a substantial medical need in the oncology market. Enzalutamide is a critical medication for metastatic castration-resistant prostate cancer, representing a high-value generic opportunity in the expanding global oncology generic market which is growing at a CAGR of 8-10%. The global oncology generic market is expanding at a CAGR of 8-10%, with Indian firms like Lupin and Sun Pharma aggressively targeting multi-billion dollar 'blockbuster' drugs. Generic Enzalutamide is a top-tier target due to the high volume of prescriptions in North America.
Lupin reported strong financial results for Q4 FY26, with consolidated profit after tax standing at ₹1,468.70 crore, up 87.72% from ₹782.40 crore in Q4 FY25. As reported by Business Standard, net sales rose 32.9% to ₹7,391.91 crore in Q4 FY26 from ₹5,562.2 crore in Q4 FY25. The company operates as a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments. By securing this approval early, Lupin ensures it is at the front of the line for generic competition in a market with few players, which typically preserves better pricing and margins. The transition from pending application to tentative approval signals clinical and bioequivalence success for the oncology drug.
